Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 8/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.44 |
| ▸ | FNTA | P49354 | 3/20 | 0.44 |
| ▸ | FNTB | P49356 | 3/20 | 0.44 |
| ▸ | MGLL | Q99685 | 2/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30297063 | 0.91 | NOD1 (0.59) | NOD1PTGS1PTGS2MGLLFAAH | |
| SCHEMBL22388827 | 0.90 | NOD1 (0.57) | NOD1PTGS1PTGS2MGLLFAAH | |
| SCHEMBL22608038 | 0.88 | NOD1 (0.59) | NOD1PTGS1PTGS2MGLLFAAH | |
| SCHEMBL5501792 | 0.85 | FOLH1 (0.49) | NOD1PTGS1PTGS2FNTAFNTB | |
| SCHEMBL15919123 | 0.85 | FOLH1 (0.49) | PTGS1PTGS2FNTAFNTB | |
| SCHEMBL16273731 | 0.85 | FOLH1 (0.49) | PTGS1PTGS2FNTAFNTB | |
| SCHEMBL10081456 | 0.81 | NOD1 (0.53) | NOD1PTGS1PTGS2FNTAFNTB | |
| SCHEMBL25130460 | 0.81 | PTGS1 (0.46) | NOD1PTGS1PTGS2FNTAFNTB | |
| SCHEMBL22598441 | 0.81 | GLO1 (0.45) | NOD1PTGS1PTGS2FNTAFNTB | |
| SCHEMBL18893551 | 0.80 | SIRT6 (0.50) | NOD1PTGS1PTGS2MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299512-A1 | IMMUNOTHERAPY COMPOSITIONS AND METHODS FOR TREATMENT OF TAUOPATHY AND TRANSGENIC MOUSE | UNM RAINFOREST INNOVATIONS | 2024-09-12 | — | — | US | claimed |
| US-20240279295-A1 | COMPOSITIONS TARGETING APOPTOSIS-ASSOCIATED SPECK-LIKE PROTEIN WITH CASPASE ACTIVATION AND RECRUITMENT DOMAIN (ASC) AND METHODS OF USE | UNM RAINFOREST INNOVATIONS | 2024-08-22 | — | — | US | claimed |
| WO-2022169665-A1 | BACTERIOPHAGE VIRUS-LIKE PARTICLE VACCINES AGAINST FLAVIVIRUS NON-STRUCTURAL PROTEIN 1 | UNM RAINFOREST INNOVATIONS (US) | 2022-08-11 | — | — | WO | claimed |
| US-20260049991-A1 | SINGLE-MOLECULE PEPTIDE SEQUENCING USING GUANIDINYLATING AGENTS | GLYPHIC BIOTECHNOLOGIES INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12523662-B2 | Antibodies that specifically bind peptides associated with the primary immunodeficiencies: Wiskott-Aldrich syndrome and x-linked agammaglobulinemia | SEATTLE CHILDREN'S HOSPITAL (US) | 2026-01-13 | — | — | US | disclosed |
| EP-4619761-A1 | SINGLE-MOLECULE PEPTIDE SEQUENCING USING DITHIOESTER AND THIOCARBAMOYL AMINO ACID REACTIVE GROUPS | Glyphic Biotechnologies, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250241872-A1 | AFFINITY MEDICANT CONJUGATE | Illudent, Inc. (US) | 2025-07-31 | — | — | US | disclosed |
| EP-4565882-A1 | PROTEIN SEQUENCING VIA COUPLING OF POLYMERIZABLE MOLECULES | Glyphic Biotechnologies, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| WO-2025064836-A2 | AMINO ACID BINDING AGENTS AND THEIR USES | GLYPHIC BIOTECHNOLOGIES, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-12259394-B2 | Protein sequencing via coupling of polymerizable molecules | GLYPHIC BIOTECHNOLOGIES, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| EP-3661528-B1 | REAGENTS FOR EXPANDING CELLS EXPRESSING RECOMBINANT RECEPTORS | JUNO THERAPEUTICS INC (US) | 2025-01-15 | — | — | EP | disclosed |
| US-7727720-B2 | Methods for detection of genetic disorders | RAVGEN, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| EP-2155894-A2 | TARGETING HOST PROTEINASES AS A THERAPEUTIC STRATEGY AGAINST VIRAL AND BACTERIAL PATHOGENS | Burnham Institute for Medical Research (US) | 2010-02-24 | — | — | EP | disclosed |
| EP-2091964-A2 | TARGETING NBS1-ATM INTERACTION TO SENSITIZE CANCER CELLS TO RADIOTHERAPY AND CHEMOTHERAPY | Southern Research Institute (US) | 2009-08-26 | — | — | EP | disclosed |
| WO-2009023306-A2 | TARGETING HOST PROTEINASES AS A THERAPEUTIC STRATEGY AGAINST VIRAL AND BACTERIAL PATHOGENS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-02-19 | — | — | WO | disclosed |
| US-7442506-B2 | Methods for detection of genetic disorders | RAVGEN, INC. (US) | 2008-10-28 | — | — | US | disclosed |
| WO-2008054726-A2 | TARGETING NBS1-ATM INTERACTION TO SENSITIZE CANCER CELLS TO RADIOTHERAPY AND CHEMOTHERAPY | SOUTHERN RESEARCH INSTITUTE (US) | 2008-05-08 | — | — | WO | disclosed |
| US-20070178478-A1 | Methods for detection of genetic disorders | RAVGEN, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20060160105-A1 | Methods for detection of genetic disorders | RAVGEN, INC. (US) | 2006-07-20 | — | — | US | disclosed |
| US-20060121452-A1 | Methods for detection of genetic disorders | RAVGEN, INC. (US) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049991-A1 | SINGLE-MOLECULE PEPTIDE SEQUENCING USING GUANIDINYLATING AGENTS | CHAMP1, S100A11, TFIP11 | NOD1 1127/4885PTGS1 3468/4885PTGS2 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.